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INTRODUCTION 
Crohn’s disease, one of the types of inflammatory bowel 
diseases (IBD), is a chronic immune-mediated disease 
resulting from an inappropriate inflammatory response to an 
environmental stimulus in a genetically susceptible host. 
Current treatment for IBD frequently involves the use of 
immunosuppressant medications: corticosteroids, 
immunomodulators (azathioprine, 6-mercaptopurine, and 
methotrexate) and anti-tumor necrosis factor alpha biologics 
(infliximab and adalimumab). These medical therapies 
effectively treat and prevent flare-ups, but also have severe 
side effects. Due to the nature of this chronic disease, the 
general management principle tends to be surgical sparing in 
order to preserve as much intact bowel for as long as possible. 
Treatment for inflammatory bowel disease has recently 
changed to include the use of immunomodulators (early 
1990s) and biologics (mid 2000s) to induce remission, yet, the 
effect of their early initiation on pediatrics’ Crohn’s disease 
course is unknown (1). The objective of this study is to 
evaluate the impact of early introduction of 
immunomodulators and biologics on surgical resection 
incidence in children with Crohn’s disease and evaluate 
temporal trends in medical management from 1983 to 2012. 
METHODS 
In this single-center retrospective comparative study, the 
medical charts of patients at the Alberta Children's Hospital 
diagnosed with Crohn’s disease from January 1, 1983 to 
January 1, 2012 and followed for a minimum of 1 year were 
reviewed. 
RESULTS 
There were 122 patients enrolled for a total of 380.4 person-
years. From 1983 to 2012, patients with early 
immunomodulators use increased from 0.0% to 61.5% while 
maintaining stable 1 and 3 year intestinal resection incidence. 
Patients (n=53) with a minimum of 3 years follow up and 
early immunomodulators or biologics use had increased 
intestinal surgery incidence (100.0% vs 37.2%, P=0.0002) and 
increased intestinal resection incidence (60.0% vs 27.9%, 
P=0.03). 
 
Figure 1. Intestinal resection use of cohort diagnosed with Crohn's 
disease during 1983 to 2012 with minimum 1 year and 3 year follow 
up. Change in percentage of cohorts with intestinal resection within 1 
or 3 years from diagnosis shown over time. Cohort sample size 
ranged from 5 to 39 patients. 
DISCUSSION AND CONCLUSIONS 
Immunomodulators and biologics are now initiated more 
frequently and earlier in treating Crohn’s disease. Intestinal 
surgery and resection incidence of children with Crohn’s 
disease has remained stable for the last 30 years. However, 
intestinal surgery and resection incidence has increased in the 
subgroup of pediatric patients with early immunomodulators 
and biologics use. The debate between top-down or step up 
medical therapy hinges on the complex interrelationship 
between medication safety profile and preventing irreversible 
bowel damage (1). This study suggests that the traditional 
step-up approach is slowly being replaced in favour of the 
more aggressive top-down strategy. Short term surgical 
incidence was independent of medical therapy, indicating that 
the outcomes in the first year following diagnosis are difficult 
to control. However, this may be attributed to the fact that 
even though there is an increase in early initiation of 
immunomodulators or biologics, these two therapies have a 
delayed effect and are slow to begin mucosal healing. This is 
very important in decreasing surgical incidence rates as 
surgical indications, such as obstructions and perforations, are 
caused by unhealed mucosa. Further evidence to clarify the 
role of early immunomodulator and biologics intervention on 
disease course may help clinicians provide realistic medical 
management expectations for patients and their families. 
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